
Shares of drugmaker Amgen AMGN.O rise 1.5% to $343.58 premarket
Company forecasts annual adj. profit per share between $21.60 and $23, above analysts' average estimate of $22.09 - data compiled by LSEG
AMGN reports Q4 adj. profit of $5.29/shr vs estimate of $4.73/shr
"While we are encouraged by strong performance from several products, including Prolia, Evenity, Repatha, and Vectibix, the beat was also aided by approximately $250 million in inventory build in the fourth quarter across the portfolio" - William Blair analyst Matt Phipps
Quarterly revenue of $9.9 billion beats analysts' expectation of $9.5 billion
Shares up 3.5% in 2025